Paper · 37204656
An international multidisciplinary consensus statement on MAFLD and the risk of CVD.
Zhou XD and 47 others. Hepatol Int, 2023. Cited by 176 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Papers, record 37204656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37204656
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cardiovascular Diseases | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Liver Diseases | Major topic |
| Non-alcoholic Fatty Liver Disease | Major topic |
| Humans | |
| Asia |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References150
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26,707,365 | Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. | Hepatology | 2016 | https://conductscience.org/library/papers/26707365 | PubMed |
| 2 | 28,714,183 | The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. | Hepatology | 2018 | https://conductscience.org/library/papers/28714183 | PubMed |
| 3 | 32,278,004 | A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. | J Hepatol | 2020 | https://conductscience.org/library/papers/32278004 | PubMed |
| 4 | 35,709,820 | Promoting the term MAFLD: China in action. | Lancet Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/35709820 | PubMed |
| 5 | 32,044,314 | MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. | Gastroenterology | 2020 | https://conductscience.org/library/papers/32044314 | PubMed |
| 6 | 32,701,591 | From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. | Chin Med J (Engl) | 2020 | https://conductscience.org/library/papers/32701591 | PubMed |
| 7 | 33,220,154 | The NAFLD-MAFLD debate: Eminence vs evidence. | Liver Int | 2021 | https://conductscience.org/library/papers/33220154 | PubMed |
| 8 | 35,004,952 | Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. | Hepatobiliary Surg Nutr | 2021 | https://conductscience.org/library/papers/35004952 | PubMed |
| 9 | 32,461,575 | From NAFLD to MAFLD: when pathophysiology succeeds. | Nat Rev Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/32461575 | PubMed |
| 10 | 36,463,192 | Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. | Cardiovasc Diabetol | 2022 | https://conductscience.org/library/papers/36463192 | PubMed |
1 to 10 of 150
See all 150 referencesCited by112
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 176 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,983,650 | Association between the red blood cell distribution width to albumin ratio and cardiovascular outcomes in MASLD patients: a national cohort study integrating machine learning. | BMC Cardiovasc Disord | 2026 | https://conductscience.org/library/papers/42983650 | PubMed |
| 42,888,835 | Metabolic Dysfunction-Associated Fatty Liver Disease-Cardiovascular-Kidney-Metabolic (MAFLD-CKM): A Modified Framework to Predict Long-Term Mortality. | Med Sci Monit | 2026 | https://conductscience.org/library/papers/42888835 | PubMed |
| 42,857,521 | Metabolic dysfunction-associated fatty liver disease: redefining the conceptual framework from nomenclature to emerging therapeutic paradigms. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42857521 | PubMed |
| 42,781,745 | The convergent roles of metabolic dysfunction, alcohol, and iron in steatotic liver disease: a review. | Biosci Rep | 2026 | https://conductscience.org/library/papers/42781745 | PubMed |
| 42,717,057 | Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework. | Nat Rev Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42717057 | PubMed |
| 42,668,768 | Odds for Presence of Metabolic Dysfunction Associated Steatotic Liver Disease ( MASLD) in Individuals with Reported Hepatic Steatosis on Ultrasound. | Pak J Med Sci | 2026 | https://conductscience.org/library/papers/42668768 | PubMed |
| 42,668,515 | The global cardiovascular-kidney-liver-metabolic burden from 1990 to 2023. | EClinicalMedicine | 2026 | https://conductscience.org/library/papers/42668515 | PubMed |
| 42,590,200 | Adiposity and Cumulative Cardiometabolic Risk Factors as Determinants of Hepatic Steatosis Severity in Postmenopausal Women. | J Clin Med | 2026 | https://conductscience.org/library/papers/42590200 | PubMed |
| 42,514,401 | ZFP90 Serves as a Transcriptional Brake on NF-κB Signaling to Attenuate Diet-Induced MASLD Progression. | Nutrients | 2026 | https://conductscience.org/library/papers/42514401 | PubMed |
| 42,500,251 | Reframing glucolipid metabolic disorders through the lens of the oral microbiome: from pathophysiological mechanisms to translational potential. | Front Nutr | 2026 | https://conductscience.org/library/papers/42500251 | PubMed |
1 to 10 of 112
See all 112 cited byGenes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AGT | 183 | PubTator's text mining | https://conductscience.org/library/genes/183 | NCBI Gene |
| GLP1R | 2,740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
| GNE | 10,020 | PubTator's text mining | https://conductscience.org/library/genes/10020 | NCBI Gene |
| INS | 3,630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| LIPE | 3,991 | PubTator's text mining | https://conductscience.org/library/genes/3991 | NCBI Gene |
| PNPLA3 | 80,339 | PubTator's text mining | https://conductscience.org/library/genes/80339 | NCBI Gene |
| PPARG | 5,468 | PubTator's text mining | https://conductscience.org/library/genes/5468 | NCBI Gene |
| PTPN6 | 5,777 | PubTator's text mining | https://conductscience.org/library/genes/5777 | NCBI Gene |
| REN | 5,972 | PubTator's text mining | https://conductscience.org/library/genes/5972 | NCBI Gene |
| SLC5A2 | 6,524 | PubTator's text mining | https://conductscience.org/library/genes/6524 | NCBI Gene |
1 to 10 of 11
See all 11 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37204656
GET https://conductscience.org/api/papers/v1/37204656/authors?page=2